Novel Genomics Technology to Address a Vast Unmet Need for Kidney and Liver Transplant Patients

In the United States alone, nearly 40,000 organ transplants [link to https://unos.org/data/] are performed annually, with kidney, liver, heart, and lung transplants being the most common.

Organ transplants have substantially improved the quality of life for hundreds of thousands of patients.

However, despite continuous advancements in surgical and medical practices, acute rejection and chronic damage of transplanted organs remain significant problems to post-transplant patient health. Acute rejection, including subclinical acute rejection (SubAR), can negatively impact patient quality of life and lead to chronic rejection — minimizing allograft survival and requiring retransplantation or other interventions.

The standard protocols for post-transplant monitoring rely on late-trailing indicators of graft function or painful, expensive, and invasive surveillance biopsies. These tests may not indicate imminent rejection until the allograft is significantly damaged, leaving clinicians and patients fewer options to improve organ health before more severe complications occur.

Doctor discusses patient organ rejection test results in atrium

Transplant Genomics is the Trusted Advisor in Personalized Diagnostics for Transplant Patients Worldwide

Since 2014, Transplant Genomics has been committed to improving organ transplant outcomes through non-invasive molecular diagnostics that detect early signs of allograft injury, allowing clinicians to differentiate among actionable causes and optimize immunosuppressive therapy. Learn more about the use of biomarker science to improve transplant outcomes [link to Biomarker Science landing page]

Our groundbreaking diagnostic tests—TruGraf Kidney, TRAC Kidney, and OmniGraf Liver —provide transplant recipients and their clinicians with valuable insights into the health of transplanted organs, and a much-needed alternative to painful biopsies.

Transplant Genomics’ extensive development pipeline includes non-invasive diagnostic and predictive tests for kidney and liver graft dysfunction, the use of multiple sample types (e.g., blood and urine) and technology platforms (e.g., NGS, qPCR, and microarrays), companion diagnostics for immunosuppressants, and immune status tests.

Transplant Genomics: Innovative Technologies Based on Core Values

At Transplant Genomics, our core values guide everything we do.

We put patients first.

There is a human life behind every specimen we test in the lab. Transplant recipients are our family members, friends, and neighbors.

We calibrate everything we do by asking, “Will this help get accurate and timely test results into the hands of a clinician so they can make the best decisions about their patient’s health?”

Explore our patient resources

We are grounded in science.

We partner with leading research institutions, transplant centers, and higher-education colleges and universities to ensure our work is backed by scientific validity and clinical utility.

Learn more about our groundbreaking work in biomarker science

We hire extraordinary talent and nurture our team members.

We actively seek out and employ people with demonstrated scientific, operational, and business achievements who are passionate about improving the quality of life for transplant patients.

As a team, we communicate and collaborate, challenge each other, and support each other in fulfilling our mission.

Explore Careers at Transplant Genomics

We celebrate our wins.

Helping patients experience better transplant outcomes is a success worth celebrating! We recognize, internally and externally, the strategies, activities, and results that improve patient care.

Learn more about our milestones in transplant success

We are committed to our customers’ success.

We partner with the hospitals and clinics that use our tests, providing the education, tools, and support they need to be successful.

We never lose sight of the connection between the tests we offer and the patients who need them.

Explore resources for transplant clinicians

nephrologist laughing with his elderly patient

Transplant Genomics: A Eurofins Company

In 2019, Eurofins Scientific acquired Transplant Genomics as part of its Clinical Diagnostics portfolio of laboratories.

Eurofins, through its subsidiaries, is the world leader in food, environment, pharmaceutical, and cosmetic products testing, and in agroscience CRO services. Eurofins is also one of the global independent market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences, and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty esoteric and molecular clinical diagnostic testing in Europe and the USA.

With over 50,000 staff in over 50 countries, operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, and purity of biological substances and products, as well as for innovative clinical diagnostics. Eurofins’ objective is to provide its customers with high-quality services, accurate results on time, and expert advice by its highly qualified staff.

Learn more about Eurofins Scientific

About Transplant Genomics